Degron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement with Takeda to Discover Molecular Glue Degraders

Collaboration will leverage Degron's GlueXplorer® platform to discover novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation Degron will receive upfront payment and

Related Keywords

Shanghai ,China ,Chris Arendt ,Degron Gluexplorer ,Yong Cang ,Lily Zou ,Shanghaitech University ,Head Of Research ,Degron Therapeutics ,Chief Scientific Officer ,